Reddit: MixedAttention: Watching

Community Take (7D)

Retail outlook on Novo Nordisk is bearish amid competitive pressures, despite a strong market position. News of Wegovy pill approval highlights ongoing developments.

The Story

News Summary

Novo Nordisk's Wegovy pill approval

Key Events

May 22:European Medicines Agency recommended approval for Wegovy.
May 18:Novo Nordisk initiated a share repurchase programme.
May 18:Wegovy's prescriptions reached approximately 137,000 despite a decline.

Sentiment: 70% bullish / 30% neutral (early) → 60% bullish / 30% cautious / 10% neutral (late)

Impact: Initially focused on Wegovy's approval and market potential, the narrative shifted to concerns over prescription trends and competition.

Analyst ConsensusBuy (39 analysts)

Target: $47 avg (-25% upside)

23 Buy · 13 Hold · 3 Sell

Signal

Divided

Confidence

60%

Based on curated news sources (not retail comments)

Over the last 7 days: Novo Nordisk's share repurchase program and regulatory approval for Wegovy are strong positives, but a decline in prescriptions poses a significant risk.

SentimentNeutral

AnalysisHype

Bullish Factors

✓Novo Nordisk initiated a share repurchase programme of up to DKK 15 billion.
✓The European Medicines Agency recommended approval for Novo Nordisk's weight-loss pill Wegovy.

Risk Factors

✗Wegovy prescriptions showed a slight weekly decline.

Analyst target

25% downside · $42–$54 range

▼ $47

Earnings

EPS: $21.85 → $21.81 (2026 vs 2027)

▼ Expected to decline 0%

Explore

$NVO

Community Take (7D)

Key Events

Bullish Factors

Risk Factors

$NVO

Community Take (7D)

Key Events

Bullish Factors

Risk Factors